Protein display by bovine herpesvirus type 1 glycoprotein B

Keil, Günther M.; Klopfleisch, Constanze; Giesow, Katrin; Veits, Jutta

doi:10.1016/j.vetmic.2010.02.011

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gB, gC, and gD proteins had been validated as subunit vaccine candidates and conferred significant protection from BoHV-1 challenge when formulated with an effective adjuvant(* 1997; Blanc et al 2012;J. CHARLES WHITBECK 1988;Keil et al 2005;Keil et al 2010;Levings et al 2015; M.J. Kaashoek'" and Oirschot*$ 1998). The gE protein could also elicit neutralizing antibodies, although it was a virulence factor of BoHV-1 (van Drunen Littel-van den Hurk 2006).…”

Section: Discussionmentioning

confidence: 99%

Polystyrene nanoparticles induce stronger cellular and more durable humoral immune responses against an inactivated bovine herpesvirus 1 isolate

Liu

Xin

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

The inactivated bovine herpesvirus type 1(BoHV-1) vaccines are generally safe and suitable for use in dairy and pregnant cattle, but induces weaker cellular immune responses and shorter antibody responses compared with the modified live virus vaccine. In this study, we used polystyrene (PS) nanoparticles (100 nm) as a carrier for purified inactivated broken BoHV-1 to improve cellular and humoral immune responses compared with the traditional inactivated vaccine. Mice were injected intramuscularly with the inactivated complex mixed with ISA206 adjuvant. Transmission electron microscopy showed that the PS nanoparticles displayed broken BoHV-1 on their surfaces. After validation of BoHV-1 and gB gC gD gE tegument proteins, it proved that the BoHV-conjugated PS nanoparticles induced higher-titer and more durable antibody responses. The inactivated BoHV-PS nanoparticle complex elicited neutralizing antibodies (titer ~2 6 ) in 5 weeks post-immunization in mice. The CD4/CD8 ratio was higher in mice immunized with PS nanoparticles compared with other groups. However, this ratio reached its maximum 1 week later than in mice immunized with ISA206+BoHV-1 or BoHV-1. Levels of interleukin (IL)-4, IL-6, and interferon-γ in followed similar patterns. In conclusion, this pilot study demonstrated that PS nanoparticles can adjuvant inactivated BoHV-1 vaccines, enhancing both cell-mediated immune responses and the duration of antibody responses. This study provides the foundation for a new development platform for inactivated vaccines, which can elicit potent cellular and humoral immune responses in animals and humans.The inactivated bovine herpesvirus type 1(BoHV-1) vaccines are generally safe and suitable for use in dairy and pregnant cattle, but induces weaker cellular immune responses and shorter antibody responses compared with the modified live virus vaccine. In this study, we used polystyrene (PS) nanoparticles (100 nm) as a carrier for purified inactivated broken BoHV-1 to improve cellular and humoral immune responses compared with the traditional inactivated vaccine. Mice were injected intramuscularly with the inactivated complex mixed with ISA206 adjuvant. Transmission electron microscopy showed that the PS nanoparticles displayed broken BoHV-1 on their surfaces. After validation of BoHV-1 and gB gC gD gE tegument proteins, it proved that the BoHV-conjugated PS nanoparticles induced higher-titer and more durable antibody responses. The inactivated BoHV-PS nanoparticle complex elicited neutralizing antibodies (titer ~2 6 ) in 5 weeks post-immunization in mice. The CD4/CD8 ratio was higher in mice immunized with PS nanoparticles compared with other groups. However, this ratio reached its maximum 1 week later than in mice immunized with ISA206+BoHV-1 or BoHV-1. Levels of interleukin (IL)-4, IL-6, and interferon-γ in followed similar patterns. In conclusion, this pilot study demonstrated that PS nanoparticles can adjuvant inactivated BoHV-1 vaccines, enhancing both cell-mediated immune responses and the duration of antibody responses. This study provides the foundation for a new development platform for inactivated vaccines, which can elicit potent cellular and humoral immune responses in animals and humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Polystyrene nanoparticles induce stronger cellular and more durable humoral immune responses against an inactivated bovine herpesvirus 1 isolate

Liu

Xin

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The use of BHV-1 as a vector of other proteins has a variety of advantages, including knowledge of the molecular biology of BHV-1, existing systems for vaccine production, and the already-widespread use of BHV-1 vaccines (so there are few or no new safety or serosurveillance concerns) (Jones and Chowdhury, 2007). The virus has been used to express IL-1β (Raggo et al , 1996), IL-2, IL-4 (Kühnle et al , 1996), IFN-γ (Raggo et al , 2000), and to display IFN-α (Keil et al , 2010). Expression of cytokines could provide an adjuvant effect for BHV-1 vaccination.…”

Section: Vaccinationmentioning

confidence: 99%

“…Parainfluenza 3 fusion (F) and hemagglutinin (HN) genes were inserted into BHV-1 (Haanes and Wardley, 1997; Cochran, 1998). In addition, insertion of an influenza hemagglutinin 1 (HA1) sequence resulted in HA1 being expressed with gG as a fusion protein on the outside of virions and infected cells (Keil et al , 2010). αHV have also been proposed for use with other viruses as chimeric vectors (Epstein and Manservigi, 2004) and as episomal systems for gene therapy (Macnab et al , 2008).…”

Section: Vaccinationmentioning

confidence: 99%

Immunity to bovine herpesvirus 1: II. Adaptive immunity and vaccinology

Levings

Roth

2013

Anim. Health. Res. Rev.

View full text Add to dashboard Cite

Bovine herpesvirus 1 (BHV-1) infection is widespread and causes a variety of diseases. Although similar in many respects to the human immune response to human herpesvirus 1, the differences in the bovine virus proteins, immune system components and strategies, physiology, and lifestyle mean the bovine immune response to BHV-1 is unique. The innate immune system initially responds to infection, and primes a balanced adaptive immune response. Cell-mediated immunity, including cytotoxic T lymphocyte killing of infected cells, is critical to recovery from infection. Humoral immunity, including neutralizing antibody and antibodydependent cell-mediated cytotoxicity, is important to prevention or control of (re-)infection. BHV-1 immune evasion strategies include suppression of major histocompatibility complex presentation of viral antigen, helper T-cell killing, and latency. Immune suppression caused by the virus potentiates secondary infections and contributes to the costly bovine respiratory disease complex. Vaccination against BHV-1 is widely practiced. The many vaccines reported include replicating and non-replicating, conventional and genetically engineered, as well as marker and non-marker preparations. Current development focuses on delivery of major BHV-1 glycoproteins to elicit a balanced, protective immune response, while excluding serologic markers and virulence or other undesirable factors. In North America, vaccines are used to prevent or reduce clinical signs, whereas in some European Union countries marker vaccines have been employed in the eradication of BHV-1 disease. AbstractBovine herpesvirus 1 (BHV-1) infection is widespread and causes a variety of diseases.

show abstract